QPI-1007: Phase I data

Interim data from an open-label, dose-escalation, international Phase I trial in 38 patients showed a single injection of QPI-1007 had no dose limiting toxicities up to and including the highest dose of 6 mg. The first portion of the trial was a single-dose escalation safety study in patients who were legally blind secondary to chronic optic nerve atrophy or retinal degeneration. ...